Loading...

Media is loading
 

Date of Award

Spring 2025

Degree Name

Master of Medical Science (Physician Assistant)

Department

Physician Assistant; College of Health Sciences

First Advisor

Michelle Thal

Abstract

Subcutaneous immunotherapy (SCIT) is a powerful treatment
option for people with refractive allergic rhinoconjunctivitis.
Immunotherapy is the only therapy that can modulate the
immune response and develop immune tolerance to common
aeroallergens such as pollen, dander, and dust mites for longer
lasting results. Although the minimum treatment period for
SCIT has been identified to be 3 years, there are still questions
regarding how long the beneficial effects of SCIT lasts after
discontinuation of therapy. There are also risks and benefits to
various accelerated SCIT dosing schedules, including cluster and rush
dosing. My presentation aims to be a comprehensive resource for
providers that need a better alternative to pharmacotherapy for
refractive allergic rhinitis and/or conjunctivitis.

Download

Share

COinS
 

Managing Allergic Rhinoconjunctivitis with Accelerated Subcutaneous Immunotherapy

Subcutaneous immunotherapy (SCIT) is a powerful treatment
option for people with refractive allergic rhinoconjunctivitis.
Immunotherapy is the only therapy that can modulate the
immune response and develop immune tolerance to common
aeroallergens such as pollen, dander, and dust mites for longer
lasting results. Although the minimum treatment period for
SCIT has been identified to be 3 years, there are still questions
regarding how long the beneficial effects of SCIT lasts after
discontinuation of therapy. There are also risks and benefits to
various accelerated SCIT dosing schedules, including cluster and rush
dosing. My presentation aims to be a comprehensive resource for
providers that need a better alternative to pharmacotherapy for
refractive allergic rhinitis and/or conjunctivitis.